Searched for
GLAND PHARMA Q2 EARNINGS
Earnings of OMCs seen weak as Q1FY27 under-recoveries bite: ReportOil companies are projected to experience ongoing challenges through FY27, primarily due to anticipated under-recoveries in Q1FY27, with LP...- Sun Pharma adds Innovcare to its fold in Rs 271.2 crore all-cash transactionIndia's largest drugmaker, Sun Pharma, is set to acquire Mumbai-based Innovcare Lifesciences for approximately $28.7 million in an all-cash...
- Accenture signals caution, but analysts see long-term IT opportunityAccenture's earnings signal tough times for IT services. Indian IT firms face weak demand and cautious client spending. While valuations ar...
- ICICI Prudential AMC shares fall 2% as IPO lock-in expiry frees up Rs 1.2 lakh crore stake for tradeICICI Prudential AMC shares dropped 2% to Rs 513 as 34.4 crore shares became eligible for trade post IPO lock-in expiry. The company's stoc...
- TCS, Infosys, Wipro, other IT stocks crash up to 8% as Accenture lowers FY26 guidanceIndian IT stocks, including TCS and Infosys, tumbled up to 8% after Accenture lowered its annual revenue growth forecast, signaling continu...
- MTAR Technologies shares surge 5%, deliver multibagger returns of 138% in just 3 monthsMTAR Technologies shares surged to a fresh 52-week high, extending a remarkable 138% rally in three months. Strong international order wins...
- Buy, Sell or Hold: Morgan Stanley raises target price on NYKAA; Elara Capital maintains buy on Devyani InternationalBrokerage views on Indian equities are mixed as Morgan Stanley raises Nykaa's target price on ambitious FY30 growth plans. Conversely, conc...
- ETMarkets PMS Talk | Dinshaw Irani of Helios India stays away from IT, doubles down on domestic consumption amid AI disruptionHelios India is steering clear of IT stocks, citing AI's disruptive potential, and instead champions India's domestic consumption. The firm...
- ETMarkets Smart Talk | AI is real, but AI valuations are not; we are in the FOMO stage of the bubble: Carnelian’s Manoj BahetyAI technology is real but its current valuations are inflated, resembling past market bubbles. Investors are urged to avoid the fear of mis...
- War, oil and El Nino: Triple threat may cut India Inc's profit margins by 150 bpsIndia Inc faces challenges ahead. Geopolitical tensions in West Asia and El Nino conditions may hurt company profits. Operating profit marg...
- Christy Mathai used market dip to buy insurance, logistics stocks; here's his sector-by-sector playbookFund Manager Christy Mathai sees easing war-driven inflation fears, expecting a shorter earnings hit. He's selectively adding to his portfo...
- Bajaj Auto sets June 24 as record date for Rs 5,632 crore share buyback. Here’s all you need to knowBajaj Auto has set June 24 as the record date for its substantial Rs 5,633 crore share buyback. Shareholders will be eligible to tender sha...
- Buy, Sell or Hold: Goldman Sachs remains neutral on Tata Motors; Nuvama maintains buy on HULBrokerages show selective optimism amidst market jitters. Goldman Sachs backs Shyam Metalics & Energy with a 10% upside target, anticipatin...
- The 30% smallcap tilt: How Abakkus Flexi Cap Fund is positioning for the next rallyAbakkus Mutual Fund is strategically allocating 30% to smallcaps within its Flexi Cap Fund, identifying mispriced opportunities despite str...
- Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan KulkarniIndian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...
- Quant Small Cap Fund raises stake in Adani Enterprises and 8 others, trims in Aurobindo Pharma and 4 moreQuant Small Cap Fund increased exposure to Adani Enterprises and eight other stocks in May while reducing holdings in Aurobindo Pharma and ...
- Honasa Consumer, 6 other stocks hit 52-week highs, rally up to 35% in a monthDespite weakness in the broader market, seven BSE 500 stocks including Honasa Consumer, Aegis Logistics and Gland Pharma scaled fresh 52-we...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Betting big on mid and smallcaps; largecaps most expensive on PEG basis, says Dinshaw IraniHelios Mutual Fund is shifting investments from large companies to mid and small companies. This move follows earnings growth trends where ...
- Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MFA promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya B...
Load More
